Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04187404
Other study ID # EOADR1-19
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 23, 2020
Est. completion date November 30, 2025

Study information

Verified date November 2023
Source Enterome
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.


Description:

EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date November 30, 2025
Est. primary completion date May 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Inclusion Criteria: 1. For inclusion in Cohort 1 patients should have adrenocortical carcinoma(ACC), or malignant pheochromocytoma/paraganglioma (MPP), as defined below for Cohorts 2A and 3A. 2. For inclusion in Cohorts 2A and 2B patients should have histologically confirmed (at primary diagnosis) unresectable locally advanced or metastatic adrenocortical carcinoma. 3. For inclusion in Cohorts 3A and 3B patients should have histologically confirmed (at primary diagnosis) unresectable malignant (defined as metastatic disease, i.e. presence of chromaffin tissue in non-chromaffin organs) pheochromocytoma/paraganglioma, and RECIST defined progression should have been documented during a maximum of an 18-months period. 4. Patients with an age = 18 years old. 5. Patients who are human leukocyte antigen (HLA)-A2 positive. 6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status = 1. 7. Patients with a life expectancy > 4 months as judged by their treating physician. 8. Patients with at least one measurable lesion according to RECIST 1.1. 9. Males or non-pregnant, non-lactating, females. 10. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol. 11. Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures. Main Exclusion Criteria: 1. Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2401 administration, unless required to treat an adverse event. 2. Patients with prior treatment with immune check-point inhibitors 3. Patients with prior exposure to EO2401. 4. Patients treated with immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications), radionuclide therapy, radiotherapy, cytoreductive therapy, or received treatment with any other investigational agent within 28 days before the first EO2401 administration. 5. Patients with an initial diagnosis of ACC less than 9 months from start of screening part 2. 6. Patients with ACC and any individual lesion according to RECIST 1.1 having a maximum diameter of more than 125 mm; irrespective if the lesion is proposed as a target lesion, or not, according to RECIST 1.1. 7. Patients with ACC with more than three organs involved by disease, combined with unresectable primary tumor. 8. Patients with ACC and uncontrolled hormonal secretion (according to the judgement of the treating physician). 9. Patients with MPP and uncontrolled blood pressure (according to the judgement of the treating physician). 10. Patients with abnormal laboratory values. 11. Patients with persistent Grade 3 or 4 toxicities. 12. Uncontrolled central nervous system (CNS) metastasis. 13. Other malignancy or prior malignancy with a disease-free interval of less than 3 years 14. Patients with clinically significant disease. 15. Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g. Guillain-Barré syndrome). 16. Patients with history of solid organ transplantation or hematopoietic stem cell transplantation. 17. Patients with history or known presence of tuberculosis. 18. Pregnant and breastfeeding patients. 19. Patients with history or presence of human immunodeficiency virus and/or potentially active hepatitis B virus/hepatitis C virus infection. 20. Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug. 21. Patients with a history of hypersensitivity to any excipient present in the pharmaceutical forms of the study treatments. 22. Patients treated with herbal remedies with immunostimulating properties or known to potentially interfere with major organ function. 23. Patients with known ongoing drug and alcohol abuse. 24. Patients with known or underlying medical or psychiatric condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or AEs. 25. Patients deprived of their liberty, under protective custody, or guardship.

Study Design


Intervention

Biological:
EO2401
Multiple dose of EO2401
Nivolumab
Multiple dose of nivolumab

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen
France Chu Lille Lille
France Centre Léon Bérard Lyon
France Assistance Publique - Hôpitaux de Marseille - Hôpital Nord Marseille
France Institut Gustave Roussy Villejuif
Germany Lmu Klinikum München
Germany Universitätsklinikum Würzburg Würzburg
Italy Azienda Ospedaliera Spedali Civili Brescia
Netherlands Amsterdam UMC, location VUmc Amsterdam
Spain Hospital Universitari Vall d'Hebron Barcelona
Sweden Karolinska University Hospital Stockholm
United States MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Enterome

Countries where clinical trial is conducted

United States,  Denmark,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events assessment Incidences of adverse events(AEs), treatment-emergent AEs (TEAEs), Serious Adverse Events ( SAEs), deaths, and laboratory abnormalities using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0. Up to 24 months
Secondary Evaluation of Progression Free Survival at 6 months Progression Free Survival according to iRECIST criteria defined as the time interval from the date of first study treatment administration to 6 months after 6 months after first treatment date from the last patient enrolled
Secondary Evaluation of survival Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause From end of treatment to at least 24 months after last patient enrollment
Secondary Assessment of the immunogenicity Assessment of the immunogenicity of the 4 components that compose EO2401 Immunogenicity will be assessed by Interferon-? ELISpot Up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Terminated NCT05948137 - F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Recruiting NCT05069220 - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor Early Phase 1
Recruiting NCT06062082 - Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
Recruiting NCT04573816 - Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Not yet recruiting NCT06045260 - "Receptor Radionuclide Therapy With 177Lu-DOTATOC Phase 2
Completed NCT00001147 - Blood Sampling for Neurochemical and Genetic Testing N/A
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00001229 - Diagnosis and Treatment of Pheochromocytoma N/A
Completed NCT01967576 - Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Phase 2
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting NCT03206060 - Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Phase 2
Not yet recruiting NCT04788927 - Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases